<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782781</url>
  </required_header>
  <id_info>
    <org_study_id>LIA-AH-1</org_study_id>
    <nct_id>NCT01782781</nct_id>
  </id_info>
  <brief_title>Local Infiltration Analgesia After Abdominal Hysterectomy</brief_title>
  <acronym>LIA</acronym>
  <official_title>Local Infiltration Analgesia After Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate traditional analgesic therapy after abdominal
      hysterectomy with single infiltration of local anesthetics in the surgical area at the end of
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a controlled, double blind, prospective, randomized and performed at Sahlgrenska
      University Hospital in Goteborg, Sweden. The injectant mixture consists of 300 mg ropivacaine
      mixed with 30 mg ketorolac and 0.5 mg epinephrine. Total volume of the solution is 156 ml.
      The normal saline injection is used in the control group in the same manner as in the LIA
      group. The parameters which would be evaluated are consumption of morphine, pain intensity
      and side effects.

      The primary objective is to evaluate whether local infiltration analgesia (LIA) into the
      operating field will reduce morphine consumption during the first 24 postoperative hours in
      patients undergoing abdominal hysterectomy (AH).

      Secondary end-points are pain intensity, incidence of nausea and vomiting, sedation
      intensity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity (NRS, Numeric Rating Score 0-10)</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea and vomiting</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation intensity (Ramsey scale)</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.
In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.
Drug: ropivacaine, ketorelac and epinephrine
In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine, ketorelac and epinephrine</intervention_name>
    <description>Active group</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Narop, Toradol and adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group</description>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring abdominal hysterectomy

        Exclusion Criteria:

          -  Body mass index &gt; 35

          -  American Society of Anesthesiologists classification &gt; 3

          -  Renal dysfunction

          -  Allergic to acetylsalicylic acid

          -  Unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Egron Thorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anil Gupta, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Orebro University Hospital, Orebro, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ove Carlsson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Olausson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olof Eckre, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven-Erik Ricksten, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Anesthesia and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatma Backman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Gynecological Surgery, Orebro University Hospital, Orebro, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Stadberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Gynecological Surgery, Sahlgrenska University Hospital, Goteborg, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Gynecological Surgery and Anesthesia and Intensive Care, Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <zip>SE41385</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Local infiltration analgesia</keyword>
  <keyword>Pain, relief</keyword>
  <keyword>Pain, Postoperative</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Ketorolac</keyword>
  <keyword>Epinephrine</keyword>
  <keyword>Adrenergic Agonists</keyword>
  <keyword>Sympathomimetics</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Analgesics, Non-Narcotic</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Opioids</keyword>
  <keyword>Morphine</keyword>
  <keyword>Pain</keyword>
  <keyword>Postoperative Complications</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Anesthetics, Local</keyword>
  <keyword>Anesthetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

